| PMN | Poly-Morpho-Nuclear Leukocytes |
|---|---|
| PMN | polymorphonuclear; polymorphonuclear neutrophil; polymorphonucleotide |
| PMNC | percentage of multinucleated cells; peripheral blood mononuclear cell |
| PMNG | polymorphonuclear granulocyte |
| PMNL | Poly-Morpho-Nuclear neutrophilic Leukocyte |
| PMNL | peripheral blood monocytes and polymorphonuclear leukocytes; polymorphonuclear leukocyte |
| PMNN | polymorphonuclear neutrophil |
| PMNR | periadenitis mucosa necrotica recurrens |
| PMN | Human neutrophil |
|---|---|
| PMN | phrenic motoneuron |
| PMN | Polymorpho-nuclear leucocytes |
| PMN | polymorphonuclear neutrophil leucocyte |
| PMN | Polymorphonuclear neutrophil |
| PMN | Polymorphonuclear |
| PMN | Polymorphonuclear granulocyte |
| PMN | Polymorphonuclear neutrophil granulocyte |
| PMN | Polymorphonuclear neutrophilic granulocytes |
| PMN | Polymorphonuclear neutrophilic leukocytes |
| PMN |
Phagocytic white blood cells with a lobed nucleus.
출처: www.genpromag.com/Glossary~LETTER~P.html
|
|---|---|
| PMN |
polymorphonuclear leukocyte; neutrophil.
출처: www.uwo.ca/pathol/glossary.html
|
| PMN |
has the meaning described in 40 CFR part 720, subpart A promulgated under the Toxic Substances Control Act, 15 USC 2601 et seq.
출처: www.setonresourcecenter.com/cfr/40CFR/P82_096.HTM
|
| PMN |
A premarket notification [510(k)] is a marketing application submitted to FDA to demonstrate that a medical device is as safe and as effective or substanntially equivalent to a legally marketed device that was or is currently on he USA market and that does not require premarket approval. The premarket notification (PMN) requirements are found in 21 CFR Psrt 807, Subpart E.
출처: www.chomericstest.com/news/glossary.htm
|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|